FILIP JANKU to AMP-Activated Protein Kinases
This is a "connection" page, showing publications FILIP JANKU has written about AMP-Activated Protein Kinases.
Connection Strength
0.048
-
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies. Cancer Res Commun. 2024 02 12; 4(2):378-387.
Score: 0.048